Chief Executive and President of The Institute of Cancer Research.
Professor Paul Workman FMedSci, FRS is Chief Executive and President of The Institute of Cancer Research (ICR).
Professor Workman is a passionate advocate of personalised molecular medicine and is an enthusiastic practitioner of multidisciplinary cancer drug discovery and development approaches to 'drugging the cancer genome'. He also conceptualised the 'Pharmacological Audit Trail' approach.
See also: The Institute of Cancer Research (ICR) - One of the world’s most influential cancer research organizations
Paul Workman News
New missile-like radioactive therapy treats prostate cancer
The Institute of Cancer Research (ICR) - 03-Jun-2021
Precisely targeted therapy shrank tumours and extends life by 38% in menRead more...
Clinical trials now up for Exscientia's world first AI-made drug
pharmaphorum - 30-Jan-2020
Partnering with Japan's DSP, a milestone is reached in OCD treatmentRead more...
Drug molecule developed using AI to undergo human trials
BBC - 30-Jan-2020
Can speed up drug discovery process using artificial intelligenceRead more...
An effective immunotherapy for advanced prostate cancer
BBC - 28-Nov-2019
Only 5% saw their tumours shrink, but may be more successful if used earlierRead more...
Pembrolizumab: effective immunotherapy for advanced head and neck cancer
BBC - 23-Nov-2019
Needs to identify those who will respond to treatment before starting immunotherapyRead more...
Discovering the structure of cancer molecule can be the key for new treatment
Medical News Today - 16-Sep-2019
By determining the DHX8's structure, scientists could discover new ways of cancer treatmentRead more...
New prostate cancer treatment for previously incurable men
Telegraph - 26-Sep-2017
Highly targeted form of radiotherapy shapes radiation beams to tumours. When prostate cancer has...Read more...
Google is developing cancer and heart attack detector
BBC - 28-Oct-2014
circulating nanoparticles monitored with a wrist-worn sensor.Read more...